title: "Assessment of RIFLE and AKIN criteria to define acute renal dysfunction for HIPEC procedures for ovarian and non ovarian peritoneal malignances".
abstract: The acute renal dysfunction (ARD) is a common complication in cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC). Our aim is evaluate the ARD post-HIPEC procedures using the RIFLE and AKIN criteria. Evaluate the risk factors and analyze ARD's impact on postoperative course.
  
  
  
  From 2011 to 2014, in a retrospective way using a prospective database were operated by HIPEC procedure. The ARD was analyzed by RIFLE and AKIN criteria. The perioperative features were analyzed and a multivariate analysis was performed to define the risk factors to develop the ARD.
  
  
  
  141 patients were treated and analyzed. The ARD was detected in 30.5% (Injury 18.4% and Failure 12.1%) when RIFLE criteria were applied. The multivariate analysis detected that decrease of pH during HIPEC [OR = 29.39 (5.09-169.76)], PCI [OR = 1.07 (1.01-1.15)] and ureteral catheters [OR = 12.71 (1.44-111.85)] were associated to the development of acute renal injury (ARI) post-HIPEC. Decrease of Na during HIPEC [OR = 1.15 (1.01-1.30)], intraoperative inotrope use [OR = 3.83 (1.12-13.09)] and PCI [OR = 1.06 (1.0-1.14)] were associated to acute renal failure (ARF) post-HIPEC. The ARD was related to a higher length of stay hospital (17.2 ± 11 vs. 13.8 ± 8 days) (p = 0.05) but no impact in early survival was observed in ARD group.
  
  
  
  The widespread use of RIFLE criteria for ARD would have major benefits in terms of accurately diagnosing patients undergone HIPEC procedures. The ARD has a detrimental impact in length of stay hospital. The knowledge of risk factors helps us to prevent the ARD post-HIPEC by means of an aggressive and multidisciplinary perioperative management.
authors.affiliation: Unit of Oncologic and Pancreatic Surgery, University Hospital Reina Sofía, Cordoba, Spain; CIBERehd, IMIBIC, University Hospital Reina Sofía, Cordoba, Spain. Electronic address: alvaroarjona@hotmail.com.
authors.forename: A
authors.initials: A
authors.lastname: Arjona-Sánchez
authors.affiliation: Unit of Oncologic and Pancreatic Surgery, University Hospital Reina Sofía, Cordoba, Spain.
authors.forename: A
authors.initials: A
authors.lastname: Cadenas-Febres
authors.affiliation: Unit of Oncologic and Pancreatic Surgery, University Hospital Reina Sofía, Cordoba, Spain.
authors.forename: J
authors.initials: J
authors.lastname: Cabrera-Bermon
authors.affiliation: Unit of Oncologic and Pancreatic Surgery, University Hospital Reina Sofía, Cordoba, Spain; CIBERehd, IMIBIC, University Hospital Reina Sofía, Cordoba, Spain.
authors.forename: F C
authors.initials: FC
authors.lastname: Muñoz-Casares
authors.affiliation: Unit of Oncologic and Pancreatic Surgery, University Hospital Reina Sofía, Cordoba, Spain.
authors.forename: A
authors.initials: A
authors.lastname: Casado-Adam
authors.affiliation: Unit of Oncologic and Pancreatic Surgery, University Hospital Reina Sofía, Cordoba, Spain; CIBERehd, IMIBIC, University Hospital Reina Sofía, Cordoba, Spain.
authors.forename: J M
authors.initials: JM
authors.lastname: Sánchez-Hidalgo
authors.affiliation: Unit of Nephrology, University Hospital Reina Sofia, Cordoba, Spain.
authors.forename: M
authors.initials: M
authors.lastname: López-Andreu
authors.affiliation: Unit of Oncologic and Pancreatic Surgery, University Hospital Reina Sofía, Cordoba, Spain; CIBERehd, IMIBIC, University Hospital Reina Sofía, Cordoba, Spain.
authors.forename: J
authors.initials: J
authors.lastname: Briceño-Delgado
authors.affiliation: Unit of Oncologic and Pancreatic Surgery, University Hospital Reina Sofía, Cordoba, Spain; CIBERehd, IMIBIC, University Hospital Reina Sofía, Cordoba, Spain.
authors.forename: S
authors.initials: S
authors.lastname: Rufián-Peña
mesh_terms: D058186:Acute Kidney Injury / Q000139:chemically induced* / Q000175:diagnosis* / Q000517:prevention & control; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D010478:Chemotherapy, Cancer, Regional Perfusion / Q000009:adverse effects / Q000379:methods*; D065426:Cytoreduction Surgical Procedures; D042241:Early Diagnosis; D005260:Female; D006801:Humans; D006979:Hyperthermia, Induced / Q000009:adverse effects*; D053208:Kaplan-Meier Estimate; D007902:Length of Stay; D008297:Male; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000601:surgery; D010348:Patient Care Team; D010534:Peritoneal Neoplasms / Q000188:drug therapy* / Q000601:surgery; D011237:Predictive Value of Tests; D012189:Retrospective Studies; D018570:Risk Assessment; D012307:Risk Factors; D016896:Treatment Outcome
keywords: Acute renal failure; HIPEC; Peritoneal carcinomatosis; RIFLE